Pinatuzumab vedotin

Pinatuzumab vedotin (INN;^[1] development codes DCDT2980S and FCU2703) is a monoclonal antibody designed for the treatment of B-cell malignancies.^[2]

Pinatuzumab vedotin

Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	CD22
Clinical data
Other names	DCDT2980S, FCU2703
ATC code	none
Identifiers
CAS Number	1313706-14-7
ChemSpider	none
UNII	6KA1906BLC
Chemical and physical data
Formula	C6748H10377N1773O2083S44
Molar mass	151081.21 g·mol−1

This drug was developed by Genentech/Roche.^{[citation needed]}